

Phone: 732-390-7750 Fax: 844-683-2244			AsteraCancerCare.org			
PATIENT REFERRAL FORM			GENERAL			
Patient Name:			Pt. D	OB:/		
Last	First	Middle				
Patient Address:						
Patient City:		Pt. State	::	_ Pt. Zip:		
Patient Phone:()			Pt. I	leight:	in.	
DX:			Pt. \	Neight:	lbs.	
Patient Allergies:						
Insurance:			ID#:			
Referred by:				#:		
Office Contact (Required):			Office Ph:(_			
			Office Fax: (_			
Office Administrator (Required):		Admiı				
 (prescription only valid for 6 month Copy of current insurance card Recent MD consultation notes: relet Allergies and current medication list Current labs required for specific methas the patient initiated treatment at y If any future lab tests are needed, pl 	vant disease edication, as r vour office?	being treated	following page(s) of this form □ No		
day of treatment. Results will be sent the above the sent	•	•	a prescription, a	nu nave patie		
 A Letter of Medical Necessity is required include diagnosis, previous treatments Benefit investigations, copay assist 	/response to	treatments a	nd be on letterh	ead with phys	ician signatu	
<i>if required by the payer. <u>Right to auto</u></i>						
notes providing supportive documenta						
days depending on the payer. The prec	-		-	-		
contact the patient to discuss cost and	financial assi	stance optior	ns. For certain m	edications, pa	tients will be	
required to register/enroll with the pha	armaceutical	company prio	or to rendered se	ervices and wi	ll receive a ca	
from an Astera Financial Counselor to a		•				
3. A pretreatment education session w	-	-				
4. Once the infusion is complete, a foll	ow-up notice	e will be faxed	l to the to the re	ferring provid	er.	

Patient Name:			DOB:	/	_/				
	Last First	Middle							
Please check the box for medication requested, attach required documentation as noted below, and fax all documents to 844.683.2244. Once all documentation is received, we will contact your patient to schedule appointment. Thanks! Medication Required Current Lab Results									
Note: Progress notes and labs must be completed within the previous 6 months for all new and renewed prescriptions.									
Actemra	CBC, Lipid Panel, Liver Function, PPD (prid	or to initiation)							
Benlysta (IV) None									
🗆 Briumvi	CBC, Quantitative Serum Immunoglobulin Hep B surface antibody and Hep B core a Confirm No Vaccinations within 4 Wee	ntibody)	3 Serology (Hep B s	urface antigen,				
🗆 Cimzia	CBC, Prior to initiation – PPD and Hep B S Hep B core antibody)	erology (Hep B surface ant	igen, Hep B	surface	antibody and				
🗆 Cinqair	Peak Flow and Other Pulmonary Functio	n Tests							
Cytoxan	CBC, CMP, UA								
🗆 Entyvio	Liver Function, PPD (prior to initiation)								
Evenity	CMP, Dexa Scan within 2 years	nfirm pt. has not had an M	ll or stroke	within p	previous year				
🗆 Fasenra	Peak Flow and Other Pulmonary Functio	n Tests							
🗆 Ilumya	 CBC, CMP, Prior to initiation – PPD and Hantibody and Hep B core antibody) Confirm up to date with vaccines and therapy or have an active infection. Experience of the section of the section. 	no live vaccinations within							
IVIG	Hematocrit, Hemoglobin, IgG Concentrat Provide dose basis in mg/kg. Doses will l				utput				
Krystexxa	G6PD Deficiency, Serum Uric Acid Levels,	Confirm Oral Urate Loweri	ng Agent D	scontir	ued				
🗆 Leqvio	Lipid Panel								
Nucala	FEV1, Peak Flow and Other Pulmonary F	unction Tests							
Nulojix	CBC, EBV Serology, Magnesium, Operativ	ve Report, Potassium, PPD	(prior to ini	tiation)					
Ocrevus	CBC, prior to initiation - Hep B Serology (Hep B core antibody)		B surface a	antibod	y and				

Orencia (IV)	Prior to initiation – PPD and Hep B Serology (Hep B surface antigen, Hep B surface antibody and Hep B core antibody)
Panhematin	CMP, Iron Studies, Prior to initiation - Urinary levels of porphobilinogen (PBG), delta aminolevulinic acid (ALA), and total porphyrin
Prolastin	Alpha 1 Proteinase Inhibitor Serum Levels and Lung Function IgA antibodies negative for patient with IgA deficiency
Radicava	None
Remicade/In	flectra (Biosimilar might be replaced if appropriate) CBC, Liver Function, Prior to initiation – PPD and Hep B Serology (Hep B surface antigen, Hep B surface antibody and Hep B core antibody)
Rituxan/Riab	ni/Truxima/Ruxience (CMS approved indications only - Biosimilar might be replaced if appropriate) CBC, prior to initiation - Hep B Serology (Hep B surface antigen, Hep B surface antibody and Hep B core antibody) Confirm No Vaccinations within 4 Weeks of Therapy
Saphnelo	Up to date with all immunizations before treatment initiation and confirm no live or live attenuated vaccines are given concurrently.
Simponi Aria	(IV) CBC, Liver Function, Prior to initiation – PPD and Hep B Serology (Hep B surface antigen, Hep B surface antibody and Hep B core antibody)
Skyrizi (IV)	Crohn's Disease Indication only - CBC, CMP (with LFTs), Prior to initiation – PPD and Hep B Serology (Hep B surface antigen, Hep B surface antibody and Hep B core antibody) Confirm No Vaccinations within 4 Weeks of Therapy or have an active infection
Soliris	Meningococcal Vaccination
Stelara (IV)	CBC, PPD
Tezspire	FEV1, Peak Flow and Other Pulmonary Function Tests
Tysabri	MRI (MS patients), TOUCH Program Registration
Vpriv	Gene Testing (GBA – Velaglucerase Alfa)
Vyepti	None
Vyvgart	CBC, Anti-AChR Antibody Positive, No Live Vaccines During Therapy
Xolair	Baseline Serum Ige, FEV1, Peak Flow, Other Pulm Function Test (all required for asthma indication only)